Mateon to develop its OT-101, a phase 3 clinical drug candidate against COVID-19
On Mar. 18, 2020, Mateon Therapeutics reported significant progress in deploying its phase 3 clinical asset, OT-101, against…
On Mar. 18, 2020, Mateon Therapeutics reported significant progress in deploying its phase 3 clinical asset, OT-101, against…
On Mar. 18, 2020, Eli Lilly announced its scientists were partnering with the Indiana State Department of Health…
On Mar. 18, 2020, Emergent BioSolutions announced an agreement with Vaxart, whereby Emergent has agreed to utilize its…
On Mar. 18, 2020, Nike CEO John Donahoe and his wife, Eileen, along with Nike Chairman Mark Parker…
On Mar. 17, 2020, CanSino Biologics announced that its recombinant novel Coronavirus Vaccine (Adenovirus Type 5 Vector) candidate…
On Mar. 17, 2020, Israel’s Health Ministry announced that it had approved a request by Pluristem Therapeutics to…
On Mar. 17, 2020, Quidel Corp. announced it had received Emergency Use Authorization (EUA) from the U.S. Food…
On Mar. 17, 2020, MannKind announced it was adjusting research and development resources that were reserved for its…
On Mar. 17, 2020, scientists reported the novel SARS-CoV-2 coronavirus that emerged in the city of Wuhan, China,…
On Mar. 17, 2020, Innovation Pharma announced details on the Material Transfer Agreement signed with a leading public…
On Mar. 17, 2020, BioReference Laboratories, an OPKO Health company, announced a collaboration with the New York City…
On Mar. 17, 2020, Pfizer and BioNTech announced the companies have agreed to a letter of intent regarding…
On Mar. 17, 2020, Regeneron announced that its scientists had isolated hundreds of virus-neutralizing, fully human antibodies from…
On Mar. 17, 2020, the virus that causes coronavirus disease 2019 (COVID-19) was stable for several hours to…
On Mar. 17, 2020, Getinge has since the outbreak of the COVID-19 pandemic seen an increased global demand…
On Mar. 16, 2020, the Hormel Institute, University of Minnesota announced published research concerning remnants of ancient viruses…
On Mar. 16, 2020, the National Institutes of Health (NIH announced that a Phase 1 clinical trial evaluating…
On Mar. 16, 2020, Moderna announced that the first participant had been dosed in the Phase 1 study…
On Mar. 16, 2020, Hologic announced the U.S. Food and Drug Administration (FDA) had granted Emergency Use Authorization…
On Mar. 16, 2020, BD (Becton, Dickinson and Company) announced the companies had submitted Emergency Use Authorization requests…
On Mar. 16, 2020, Sanofi and Regeneron Pharma announced they have started a clinical program evaluating Kevzara (sarilumab)…
On Mar. 16, 2020, Meridian Bioscience announced its increased commitment to the global fight against COVID-19 by making…
On Mar. 15, 2020, the National Institutes of Health (NIH) informed its staff that it had its first…
On Mar. 15, 2020, Iceland health authorities and deCode Genetics announced they began comprehensive screening for the virus…
On Mar. 13, 2020, IDEXX Laboratories announced the company had seen no positive results in pets to date…
On Mar. 13, 2020, Johnson & Johnson announced that its Janssen Pharmaceutical Companies have entered a collaboration with…
On Mar. 13, 2020, BioReference Laboratories, an OPKO company, announced it had begun accepting specimens for testing of…
On Mar. 13, 2020, Luminex announced that four independent clinical laboratories had validated laboratory developed tests (LDTs) for…
On Mar. 13, 2020, Roche announced the U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization…
On Mar. 13, 2020, Thermo Fisher Scientific announced the U.S. Food and Drug Administration (FDA) has issued an emergency…